Skip to main content

Transgenomic Enters Mutation Discovery Partnership with Novartis

NEW YORK, Dec. 2 (GenomeWeb News) - Transgenomic today said that it has entered into "several specific agreements" with Novartis Pharmaceuticals to provide mutation discovery services to support translational research programs in oncology.

Transgenomic said that the goal of the collaboration is to support biomarker discovery efforts in clinical trials by identifying genetic mutations that correlate with patients' response or responses to cancer therapeutics. Transgenomic said it has already performed proof-of-principle work and begun to deliver data for the projects.

The companies have several specific project agreements, according to Transgenomic, including a clinical assay/protocol development project.

"Novartis Oncology is dedicated to incorporating knowledge of genomic changes associated with cancer into the drug development process," said Kenneth Culver, global head of translational medicine at Novartis Oncology. He added that the company is using Transgenomic's WAVE technology to detect low-abundance mutations in clinical specimens, and to scan for mutations "rather than develop specific assays for each potential mutation."

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.